POMDOCTOR Ltd

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, ONC has a market cap of 30.4B. Regarding current trading prices, POM is priced at $0.40, while ONC trades at $284.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas ONC's P/E ratio is 114.54. In terms of profitability, POM's ROE is +0.07%, compared to ONC's ROE of +0.07%. Regarding short-term risk, POM is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ONC's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, POM is priced at $0.40, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas WBA's P/E ratio is -1.64. In terms of profitability, POM's ROE is +0.07%, compared to WBA's ROE of -0.39%. Regarding short-term risk, POM is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check WBA's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, DFTX has a market cap of 1.8B. Regarding current trading prices, POM is priced at $0.40, while DFTX trades at $18.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas DFTX's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to DFTX's ROE of -0.84%. Regarding short-term risk, POM is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check DFTX's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, POM is priced at $0.40, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas HROWL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to HROWL's ROE of -0.10%. Regarding short-term risk, POM is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HROWL's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, POM is priced at $0.40, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas HROWM's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to HROWM's ROE of -0.10%. Regarding short-term risk, POM is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HROWM's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, LFMDP has a market cap of 1B. Regarding current trading prices, POM is priced at $0.40, while LFMDP trades at $22.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas LFMDP's P/E ratio is -10.08. In terms of profitability, POM's ROE is +0.07%, compared to LFMDP's ROE of +2.82%. Regarding short-term risk, POM is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check LFMDP's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, CGEM has a market cap of 796.9M. Regarding current trading prices, POM is priced at $0.40, while CGEM trades at $13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas CGEM's P/E ratio is -4.06. In terms of profitability, POM's ROE is +0.07%, compared to CGEM's ROE of -0.46%. Regarding short-term risk, POM is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check CGEM's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, ATAI has a market cap of 696M. Regarding current trading prices, POM is priced at $0.40, while ATAI trades at $3.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas ATAI's P/E ratio is -4.45. In terms of profitability, POM's ROE is +0.07%, compared to ATAI's ROE of -1.08%. Regarding short-term risk, POM is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ATAI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, HITI has a market cap of 216.1M. Regarding current trading prices, POM is priced at $0.40, while HITI trades at $2.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas HITI's P/E ratio is -5.35. In terms of profitability, POM's ROE is +0.07%, compared to HITI's ROE of -0.40%. Regarding short-term risk, POM is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HITI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, LFMD has a market cap of 191.6M. Regarding current trading prices, POM is priced at $0.40, while LFMD trades at $3.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas LFMD's P/E ratio is -15.31. In terms of profitability, POM's ROE is +0.07%, compared to LFMD's ROE of +2.82%. Regarding short-term risk, POM is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check LFMD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, POM is priced at $0.40, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas LFLY's P/E ratio is -0.04. In terms of profitability, POM's ROE is +0.07%, compared to LFLY's ROE of +0.25%. Regarding short-term risk, POM is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check LFLY's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, YI has a market cap of 57M. Regarding current trading prices, POM is priced at $0.40, while YI trades at $6.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas YI's P/E ratio is -2.31. In terms of profitability, POM's ROE is +0.07%, compared to YI's ROE of +0.11%. Regarding short-term risk, POM is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check YI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, PETS has a market cap of 52.6M. Regarding current trading prices, POM is priced at $0.40, while PETS trades at $2.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas PETS's P/E ratio is -0.79. In terms of profitability, POM's ROE is +0.07%, compared to PETS's ROE of -1.22%. Regarding short-term risk, POM is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check PETS's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, POM is priced at $0.40, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas RAD's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.07%, compared to RAD's ROE of +2.76%. Regarding short-term risk, POM is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check RAD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, RNTX has a market cap of 34.2M. Regarding current trading prices, POM is priced at $0.40, while RNTX trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas RNTX's P/E ratio is -0.44. In terms of profitability, POM's ROE is +0.07%, compared to RNTX's ROE of -2.17%. Regarding short-term risk, POM is more volatile compared to RNTX. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check RNTX's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, KYNB has a market cap of 28.2M. Regarding current trading prices, POM is priced at $0.40, while KYNB trades at $6.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas KYNB's P/E ratio is -0.54. In terms of profitability, POM's ROE is +0.07%, compared to KYNB's ROE of -1.26%. Regarding short-term risk, POM is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check KYNB's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, POM is priced at $0.40, while MEDS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas MEDS's P/E ratio is -0.31. In terms of profitability, POM's ROE is +0.07%, compared to MEDS's ROE of -0.26%. Regarding short-term risk, POM is more volatile compared to MEDS. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check MEDS's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, MSLE has a market cap of 10.3M. Regarding current trading prices, POM is priced at $0.40, while MSLE trades at $8.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas MSLE's P/E ratio is 3.11. In terms of profitability, POM's ROE is +0.07%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, POM is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check MSLE's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, POM is priced at $0.40, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas CJJD's P/E ratio is -0.46. In terms of profitability, POM's ROE is +0.07%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, POM is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check CJJD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, NEUP has a market cap of 8.5M. Regarding current trading prices, POM is priced at $0.40, while NEUP trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas NEUP's P/E ratio is -6.58. In terms of profitability, POM's ROE is +0.07%, compared to NEUP's ROE of -15.38%. Regarding short-term risk, POM is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check NEUP's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, POM is priced at $0.40, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas SSY's P/E ratio is -2.86. In terms of profitability, POM's ROE is +0.07%, compared to SSY's ROE of -0.18%. Regarding short-term risk, POM is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check SSY's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, HKPD has a market cap of 6.7M. Regarding current trading prices, POM is priced at $0.40, while HKPD trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas HKPD's P/E ratio is 3.60. In terms of profitability, POM's ROE is +0.07%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, POM is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HKPD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, AIXC has a market cap of 5.9M. Regarding current trading prices, POM is priced at $0.40, while AIXC trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas AIXC's P/E ratio is 0.40. In terms of profitability, POM's ROE is +0.07%, compared to AIXC's ROE of -0.73%. Regarding short-term risk, POM is more volatile compared to AIXC. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check AIXC's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, BGMSP has a market cap of 5.7M. Regarding current trading prices, POM is priced at $0.40, while BGMSP trades at $2.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas BGMSP's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to BGMSP's ROE of -7.22%. Regarding short-term risk, POM is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check BGMSP's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, POM is priced at $0.40, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas MDVL's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.07%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, POM is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check MDVL's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, POM is priced at $0.40, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas ATNFW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, POM is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check ATNFW's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, NVOH has a market cap of 1.9M. Regarding current trading prices, POM is priced at $0.40, while NVOH trades at $21.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas NVOH's P/E ratio is 11.15. In terms of profitability, POM's ROE is +0.07%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check NVOH's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, BGMS has a market cap of 1.7M. Regarding current trading prices, POM is priced at $0.40, while BGMS trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas BGMS's P/E ratio is -0.06. In terms of profitability, POM's ROE is +0.07%, compared to BGMS's ROE of -1.87%. Regarding short-term risk, POM is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check BGMS's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, POM is priced at $0.40, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas AZNH's P/E ratio is 38.35. In terms of profitability, POM's ROE is +0.07%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check AZNH's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, POM is priced at $0.40, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, POM's ROE is +0.07%, compared to LFLYW's ROE of +0.25%. Regarding short-term risk, POM is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check LFLYW's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, POM is priced at $0.40, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas BIMI's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, POM is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check BIMI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, POM is priced at $0.40, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas IPXL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, POM is more volatile compared to IPXL. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check IPXL's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, POM is priced at $0.40, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas POZN's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to POZN's ROE of +0.61%. Regarding short-term risk, POM is more volatile compared to POZN. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check POZN's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, POM is priced at $0.40, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas CPD's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to CPD's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check CPD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 42.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, POM is priced at $0.40, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -7.92, whereas ESRX's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, POM is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ESRX's competition here